Skip to main content

Table 5 Antibiotic susceptibility results of extended spectrum beta lactamase (ESBL) and non-ESBL Klebsiella pneumoniae isolates

From: Klebsiella pneumoniae bloodstream infections at a South African children’s hospital 2006–2011, a cross-sectional study

Antibiotic

Number of resistant isolates

Non-ESBL KP

ESBL KP

n/N

(%)

n/N

(%)

Ampicillin

71/71

(100)

339/339

(100)

Co-amoxyclav

5/71

(7.1)

280/331

(84.6)

Cefotaxime

0/71

(0)

339/339

(100)

Ceftazidime

0/71

(0)

339/339

(100)

Cefepime

0/71

(0)

339/339

(100)

Ciprofloxacin

0/71

(0)

142/339

(41.9)

Cotrimoxazole

18/71

(25.4)

313/339

(92.3)

Amikacin

0/71

(0)

98/339

(28.9)

Gentamicin

4/71

(5.6)

319/338

(94.4)

Piperacillin-Tazobactam

2/67

(3.0)

136/282

(48.2)

Ertapenem

0/67

(0)

2/338

(0.6)

Imipenem

0/71

(0)

0/338

(0)

Meropenem

0/71

(0)

0/338

(0)

  1. KP Klebsiella pneumoniae, ESBL KPBSI Extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae bloodstream infection, co-amoxyclav amoxicillin-clavulanic acid co-formulation, n/N stratum specific proportions